Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Journey Medical Q3 2026 Results: Net Loss of $1.31M, Loss Narrows

Journey Medical Corp reported a 16.7% increase in total revenue to $53.4 million for the nine months ended September 30, 2026, compared to the prior year. The company significantly reduced its net loss from $10.2 million to $3.9 million over the same period, driven by improved operating margins and lower research and development expenses.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue19.017.6
Profit before tax-1.3-2.3
Net income-1.3-2.3
EPS (diluted, $ a share)$-0.05$-0.09

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+7.6%
Operating margin-2.8%
Source

10-Q filed with the SEC, NASDAQ: DERM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Journey Medical Corp: key numbers

Share price
$3.90Close, Nov 17
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Journey Medical Corp

All →
4:07 PM ET 8-K
Financial Results

Journey Medical Financial Results

Journey Medical Corporation reported third quarter 2026 financial results, featuring total revenues of $19.0 million, an 8% increase year-over-year. Growth was primarily driven by its oral rosacea treatment, Emrosi, which saw an 84% revenue increase to $9.0 million. The company's net loss narrowed to $1.3 million compared to $2.3 million in the prior-year period.

“We continued to make progress during the third quarter, delivering year-over-year revenue growth, a higher gross margin, and positive EBITDA. Third quarter sales of Emrosi®, our best-in-class oral rosacea treatment, increased by 84% compared to the prior-year period, driven by growth in prescription demand and continued improvement in the mix of prescriptions reimbursed by health plans.”

Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer

“Building on this progress and with over $22 million in cash, we believe we are well-positioned to advance our mission of delivering value to our dermatology customers and their patients while building long-term shareholder value.”

Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.